Mutual Of America Capital Management LLC Biocryst Pharmaceuticals Inc Transaction History

Mutual Of America Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 02, 2024	SELL	$4.89 - $7.65 $42,890 - $67,098	-8,771 Reduced 3.96%	212,781 $1.08 Million
Q4 2023 Jan 26, 2024	SELL	$4.98 - $6.77 $18,779 - $25,529	-3,771 Reduced 1.67%	221,552 $1.33 Million
Q3 2023 Nov 09, 2023	BUY	$6.71 - $7.92 $37,502 - $44,264	5,589 Added 2.54%	225,323 $1.6 Million
Q2 2023 Aug 11, 2023	BUY	$6.96 - $8.81 $1,552 - $1,964	223 Added 0.1%	219,734 $1.55 Million
Q1 2023 May 04, 2023	SELL	$7.94 - $11.84 $1.24 Million - $1.85 Million	-156,317 Reduced 41.59%	219,511 $1.83 Million
Q4 2022 Feb 10, 2023	BUY	$10.5 - $14.2 $1.78 Million - $2.4 Million	169,090 Added 81.79%	375,828 $4.31 Million
Q2 2022 Aug 10, 2022	SELL	$7.89 - $17.88 $30,195 - $68,426	-3,827 Reduced 1.82%	206,738 $2.19 Million
Q1 2022 May 02, 2022	SELL	$11.56 - $19.76 $14,947 - $25,549	-1,293 Reduced 0.61%	210,565 $3.42 Million
Q4 2021 Feb 03, 2022	BUY	$11.18 - $15.46 $317,791 - $439,450	28,425 Added 15.5%	211,858 $2.93 Million
Q3 2021 Nov 10, 2021	BUY	$14.21 - $17.65 $2.61 Million - $3.24 Million	183,433 New	183,433 $2.64 Million

280

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Mutual Of America Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Mutual Of America Capital Management LLC with notifications on news.